Asset sale Pending
Collegium Pharmaceutical acquisition of AZSTARYS business
US$650m consideration
Announced 19 Mar 2026
Advisers
- Target
- AZSTARYS business
- Acquirer
- Collegium Pharmaceutical
- Seller
- Corium Therapeutics Holdings
- Target based in
- United States (unverified)
- Buyer based in
- United States
- Seller based in
- United States
- Sector
- Pharma
In the league tables
Similar deals
- UCB acquisition of Neurona Therapeutics Apr 2026 · US$650m · Biotech
- Teva Pharmaceuticals acquisition of Emalex Biosciences Apr 2026 · US$700m · Pharma
- Otsuka acquisition of Transcend Therapeutics Mar 2026 · US$700m · Biotech
- ANI Pharmaceuticals acquisition of Egetis 2026 · US$560m · Pharma
- Veloxis Pharmaceuticals acquisition of AiCuris Anti-infective Cures AG Feb 2026 · US$913m · Pharma
Sources
- 2026 Centerview Partners: Exclusive financial advisor to Corium on its sale of AZSTARYS to Collegium Pharmaceutical centerviewpartners.com
- 19 Mar 2026 Press release (EX-99.1, exhibit), Collegium to Acquire AZSTARYS® from Corium sec.gov
- 24 Mar 2026 Goodwin Advises Collegium on Acquisition of AZSTARYS® From Corium Therapeutics for $650 Million Upfront and Up To $135 Million in Milestones goodwinlaw.com


